Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp (AHCO) filed a Form 3 Initial Statement of Beneficial Ownership for Daniel Edward McFadden, who has been appointed as the company's Chief Business Systems Officer. The filing, dated June 28, 2025, discloses McFadden's initial beneficial ownership position in the company.
Key ownership details:
- McFadden beneficially owns 53,958 shares of common stock in the form of restricted stock units (RSUs)
- The ownership is held directly (D)
- The RSUs will be settled in common stock upon vesting
The filing was executed by Richard Rew as attorney-in-fact for Daniel McFadden on June 26, 2025. This Form 3 filing is required under Section 16(a) of the Securities Exchange Act of 1934 for new officers, directors, or beneficial owners of more than 10% of a company's securities.
AdaptHealth Corp (NASDAQ: AHCO) has filed Amendment No. 1 to its 2024 Annual Report (Form 10-K/A) to address an omission in the original filing regarding equity compensation plan information. The amendment specifically updates Part III, Item 12 to include the previously omitted Equity Compensation Plan Table.
Key equity compensation details as of December 31, 2024:
- 5,115,684 securities to be issued under the A&R 2019 Stock Incentive Plan with weighted-average exercise price of $9.67
- 9,138,317 securities remaining available for future issuance under the A&R 2019 Plan
- 622,398 shares available under the 2019 Employee Stock Purchase Plan
- 782,991 securities granted to CEO Suzanne Foster as employment inducement outside the approved plans
The company is classified as a large accelerated filer with a market value of approximately $1.07 billion for non-affiliate shares as of June 28, 2024. As of February 21, 2025, AdaptHealth had 134,867,011 shares of Common Stock outstanding.